Transient elastography as a screening method for chronic liver disease in apparently healthy population. Results from de ETHON cohort

Llop, Elba; Iruzubieta, Paula; Perelló, Christie; Cabezas, Joaquín; Escudero-García, Desamparados; González, Matías; Conde, Marta Hernández; Puchades, Laura; Loste, María Teresa Arias; Serra, M.Á.; Crespo, Javier; Panero, José Luis Calleja

doi:10.1016/s0168-8278(18)31525-3

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current guidelines do not recommend widespread or community screening, mainly due to the perceived associated direct and indirect medical costs [20,39]. However, some national and international initiatives (ETHON project, Spain [129]; international LiverScreen project [NCT03789825]) are currently investigating the effectiveness of screening the general population for significant liver disease. Screening at-risk patients has been shown to be cost-effective in several studies across different countries [130][131][132].…”

Section: Which Patient Populations Should Be Screened For Nafld?mentioning

confidence: 99%

Non-invasive diagnosis and staging of non-alcoholic fatty liver disease

et al. 2022

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is considered to be the hepatic manifestation of the metabolic syndrome and is characterized by ectopic accumulation of triglycerides in the cytoplasm of hepatocytes, i.e., steatosis. NAFLD has become the most common chronic liver disease, with an estimated global prevalence of 25%. Although the majority of NAFLD patients will never experience liver-related complications, the progressive potential of NAFLD is indisputable, with 5–10% of subjects progressing to cirrhosis, end-stage liver disease, or hepatocellular carcinoma. NAFLD patients with advanced fibrosis are at the highest risk of developing cardiovascular and cirrhosis-related complications. Liver biopsy has hitherto been considered the reference method for evaluation of hepatic steatosis and fibrosis stage. Given the limitations of biopsy for widescale screening, non-invasive tests (NITs) for assessment of steatosis and fibrosis stage, including serum-based algorithms and ultrasound- and magnetic resonance-based methods, will play an increasing role in the management of NAFLD patients. This comprehensive review presents the advantages and limitations of NITs for identification of steatosis and advanced fibrosis in NAFLD. The clinical implications of using NITs to identify and manage NAFLD patients are also discussed.

show abstract

Section: Which Patient Populations Should Be Screened For Nafld?mentioning

confidence: 99%

Non-invasive diagnosis and staging of non-alcoholic fatty liver disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Current guidelines do not recommend widespread or community screening, mainly due to the perceived associated direct and indirect medical costs [31,32,41]. However, some national and international initiatives (ETHON project, Spain [42]; international LiverScreen project [NCT03789825]) are currently investigating the effectiveness of screening the general population for significant liver disease, considering evidence that this may be a cost-effective strategy. Screening at-risk patients has been shown to be costeffective in several studies across different countries [43][44][45].…”

Section: Which Patient Populations Should Be Screened?mentioning

confidence: 99%

Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice

Augustín

Ahmed

Alkhouri

et al. 2020

JGLD

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) prevalence has increased in the past two decades, resulting in a significant but under-recognised public health burden. This impacts the prevalence of advanced fibrosis, end-stage liver disease and associated extrahepatic manifestations. To understand the challenges in recognising patients with advanced fibrosis due to NASH and develop a standardised approach to screen these patients, the authors of this document provided their opinions and expertise from practice and published evidence to identify key challenges and current approaches for diagnosing NASH. The severity of liver fibrosis due to NASH is the main indicator of associated morbidity and mortality outcomes. Therefore, identifying patients with, or at risk of, advanced fibrosis due to NASH and linking them to appropriate care is critical. This can be challenging due to a lack of awareness of NASH among healthcare professionals and a lack of standardised protocols for identifying patients. Simple noninvasive tests may provide an opportunity to facilitate early identification of these patients. This article proposes a simple, universally applicable diagnostic algorithm for use in clinical practice, that includes sequential use of noninvasive tests, ideally a biological marker and an imaging technique, which may help to facilitate early diagnosis of these patients. In the opinion of the authors, early detection of advanced fibrosis is fundamental in the efforts to halt the progression of NASH and diagnostic algorithms may facilitate pre-emptive interventions to curtail the disease.

show abstract

Transient elastography as a screening method for chronic liver disease in apparently healthy population. Results from de ETHON cohort

Cited by 2 publications

References 0 publications

Non-invasive diagnosis and staging of non-alcoholic fatty liver disease

Non-invasive diagnosis and staging of non-alcoholic fatty liver disease

Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice

Contact Info

Product

Resources

About